Needham raised the firm’s price target on Acadia Pharmaceuticals (ACAD) to $30 from $27 and keeps a Buy rating on the shares.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ACAD:
- ACADIA Pharmaceuticals: Buy Rating Affirmed Amid Legal Victory and Promising R&D Prospects
- District court finds Aurobindo infringes Acadia Pharmaceuticals patent claims
- Acadia Pharmaceuticals files to sell 43.58M shares of common stock for holders
- ACADIA Pharmaceuticals Reports Strong Q1 Earnings Growth
- Positive Outlook for ACADIA Pharmaceuticals: Buy Rating Affirmed Amid Strategic Growth Initiatives and Promising Pipeline Developments
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue